Literature DB >> 24899541

Dornase alpha inhalations as a treatment option for recurrent lower respiratory tract infections in a child with Sotos syndrome.

Philipp Eickhoff1, Tamas Fazekas, Hans Wank, Ulrike Kastner.   

Abstract

Recurrent episodes of lower respiratory tract infections (LRTIs) are a rare complication of muscular hypotonia in patients with Sotos syndrome. We report on a male child suffering from repeated LRTIs including bronchitis, pneumonia, and atelectasis during infancy despite inhalations with salbutamol and fluticasone combined with manual chest percussion therapy. After initiation of dornase alpha inhalations in addition to the current treatment, we observed an improvement in the respiratory symptoms as well as a reduction in the rate of hospitalizations and in the occurrence of LRTIs. We assume that dornase alpha inhalations, in combination with airway clearance techniques, reduced the viscosity of airway secretions and by this improved mucociliary clearance and coughing efficiency.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24899541     DOI: 10.1007/s00508-014-0552-2

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  16 in total

Review 1.  Current concepts of respiratory complications of neuromuscular disease in children.

Authors:  C M Schramm
Journal:  Curr Opin Pediatr       Date:  2000-06       Impact factor: 2.856

2.  CEREBRAL GIGANTISM IN CHILDHOOD. A SYNDROME OF EXCESSIVELY RAPID GROWTH AND ACROMEGALIC FEATURES AND A NONPROGRESSIVE NEUROLOGIC DISORDER.

Authors:  J F SOTOS; P R DODGE; D MUIRHEAD; J D CRAWFORD; N B TALBOT
Journal:  N Engl J Med       Date:  1964-07-16       Impact factor: 91.245

Review 3.  Airway clearance in Duchenne muscular dystrophy.

Authors:  Richard M Kravitz
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

Review 4.  Respiratory issues in the management of children with neuromuscular disease.

Authors:  Howard B Panitch
Journal:  Respir Care       Date:  2006-08       Impact factor: 2.258

Review 5.  Management of airway clearance in neuromuscular disease.

Authors:  Louis J Boitano
Journal:  Respir Care       Date:  2006-08       Impact factor: 2.258

Review 6.  Mucoactive agents for airway mucus hypersecretory diseases.

Authors:  Duncan F Rogers
Journal:  Respir Care       Date:  2007-09       Impact factor: 2.258

Review 7.  Respiratory medicines for children: current evidence, unlicensed use and research priorities.

Authors:  A R Smyth; A Barbato; N Beydon; H Bisgaard; K de Boeck; P Brand; A Bush; B Fauroux; J de Jongste; M Korppi; C O'Callaghan; M Pijnenburg; F Ratjen; K Southern; D Spencer; A Thomson; H Vyas; A Warris; P J Merkus
Journal:  Eur Respir J       Date:  2009-10-19       Impact factor: 16.671

8.  Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis.

Authors:  S G McKenzie; S Chowdhury; B Strandvik; M E Hodson
Journal:  Pediatr Pulmonol       Date:  2007-10

9.  DNase and atelectasis in non-cystic fibrosis pediatric patients.

Authors:  Tom Hendriks; Matthijs de Hoog; Maarten H Lequin; Annick S Devos; Peter J F M Merkus
Journal:  Crit Care       Date:  2005-05-20       Impact factor: 9.097

Review 10.  Sotos syndrome.

Authors:  Geneviève Baujat; Valérie Cormier-Daire
Journal:  Orphanet J Rare Dis       Date:  2007-09-07       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.